Society guideline links: Cardiomyopathy

Introduction — This topic includes links to society and government-sponsored guidelines from selected countries and regions around the world. We will update these links periodically; newer versions of some guidelines may be available on each society's website. Some societies may require users to log in to access their guidelines.

The recommendations in the following guidelines may vary from those that appear in UpToDate topic reviews. Readers who are looking for UpToDate topic reviews should use the UpToDate search box to find the relevant content.

Links to related guidelines are provided separately:

●(See "Society guideline links: Heart failure in adults".)

●(See "Society guideline links: Heart failure in children".)

●(See "Society guideline links: Arrhythmias in adults".)

●(See "Society guideline links: Arrhythmias in children".)

●(See "Society guideline links: Syncope".)

●(See "Society guideline links: Myocarditis".)

●(See "Society guideline links: Management of cardiovascular diseases during pregnancy".)

International

●Heart Rhythm Society (HRS): Expert consensus statement on evaluation, risk stratification, and management of arrhythmogenic cardiomyopathy (2019)

●HRS/European Heart Rhythm Association (EHRA): Expert consensus statement on the state of genetic testing for the channelopathies and cardiomyopathies (2011, reaffirmed 2018)

United States

●American College of Radiology (ACR): ACR Appropriateness Criteria on nonischemic myocardial disease with clinical manifestations (ischemic cardiomyopathy already excluded) (2021)

●American Heart Association (AHA): Scientific statement on genetic testing for inherited cardiovascular diseases (2020)

●AHA/American College of Cardiology (ACC): Guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy (2020)

●AHA: Scientific statement on cardiomyopathy in children – Classification and diagnosis (2019)

●American College of Medical Genetics and Genomics (ACMG): Clinical practice resource on genetic evaluation of cardiomyopathy (2018)

●Heart Failure Society of America (HFSA): Practice guideline on genetic evaluation of cardiomyopathy (2018)

●AHA: Scientific statement for the management of cardiac involvement associated with neuromuscular diseases (2017)

●AHA: Scientific statement on the current diagnostic and treatment strategies for specific dilated cardiomyopathies (2016)

●AHA/ACC: Scientific statement on the eligibility and disqualification recommendations for competitive athletes with cardiovascular abnormalities – Hypertrophic cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy and other cardiomyopathies, and myocarditis (2015)

●AHA/ACC: Scientific statement on the eligibility and disqualification recommendations for competitive athletes with cardiovascular abnormalities – Preamble, principles, and general considerations (2015)

●ACC: The MOGE(S) classification of cardiomyopathy for clinicians (2014)

●AHA/ACC: Scientific statement for the assessment of the 12-lead ECG as a screening test for detection of cardiovascular disease in healthy general populations of young people (12–25 years of age) (2014)

●American Society of Echocardiography (ASE): Clinical recommendations for multimodality cardiovascular imaging of patients with hypertrophic cardiomyopathy (2011)

●AHA/ACC/European Society of Cardiology (ESC): The role of endomyocardial biopsy in the management of cardiovascular disease (2007)

Europe

●European Society of Cardiology (ESC): Guidelines for the management of cardiomyopathies (2023)

•ESC: Guidelines on diagnosis and management of hypertrophic cardiomyopathy (2014)

●European Association of Preventive Cardiology (EAPC): Position statement on recommendations for participation in competitive and leisure time sport in athletes with cardiomyopathies, myocarditis, and pericarditis (2018)

●Heart Rhythm Society (HRS)/European Heart Rhythm Association (EHRA): Expert consensus statement on the state of genetic testing for the channelopathies and cardiomyopathies (2011, reaffirmed 2018)

●ESC: Position statement on classification of the cardiomyopathies (2008)

●American Heart Association (AHA)/American College of Cardiology (ACC)/ESC: The role of endomyocardial biopsy in the management of cardiovascular disease (2007)

United Kingdom

●National Institute for Health and Care Excellence (NICE): Interventional procedures guidance on non-surgical reduction of the myocardial septum (2004)

Australia–New Zealand

●Cardiac Society of Australia and New Zealand (CSANZ): Position statement on the diagnosis and management of arrhythmogenic right ventricular cardiomyopathy, update (2019)

●CSANZ: Diagnosis and management of familial dilated cardiomyopathy – Position statement (2016)

●CSANZ: Diagnosis and management of hypertrophic cardiomyopathy – Position statement (2016)

Japan

●[In Japanese] Japanese Circulation Society (JCS): Guideline on diagnosis and treatment of cardiomyopathies (2018)